A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B

Adrian Streinu‐Cercel(Carol Davila University of Medicine and Pharmacy), Patricia Méndez, Stuart Roberts, Y.J. Kim, Kosh Agarwal(King's College - North Carolina), William Sievert(Monash Health), Demi Niforos, B. Symonds, Sang Hoon Ahn(Yonsei University), Edward Gane(University of Auckland), W. Cheng
Journal of Hepatology
January 1, 2017
10.1016/s0168-8278(17)31850-0
Cited by 34

Related Papers

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
|The Lancet|1997|501
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
|Hepatology International|2020|295